The trial’s suspension comes after a new study revealed that COVID-19 patients who received hydroxychloroquine, which treats malaria and lupus, experienced a significantly higher risk of dying than those who didn’t receive it. The results suggested that the drug put COVID-19 patients at a higher risk of irregular heartbeats that could end in cardiac arrest.
While the drug’s safety is being reviewed in the context of treating COVID-19 patients, the WHO has maintained that the drug is generally safe for patients with malaria or autoimmune diseases, The Hill reported. The FDA in April cautioned that hydroxychloroquine should only be taken in a clinical trial or hospital.
Read the full article here.
More articles on pharmacy:
AstraZeneca gets $1B from US to produce COVID-19 vaccine
7 things to know about startup drugmaker Phlow
Consumers still feel comfortable picking up prescriptions at pharmacies, survey says
Consumers still feel comfortable picking up prescriptions at pharmacies, survey says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
